Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DMAC) in HIV-Positive Patients
NCT00000907 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate the effects of stopping preventive therapy for DMAC in HIV-positive patients who (1) have been treated for DMAC for at least 12 months and are now free of any signs of DMAC for at least 16 weeks, and (2) have improved immune systems (CD4 cell counts greater than or equal to 100 cells/mm3) due to anti-HIV drug therapy. DMAC is a serious and sometimes life-threatening infection that usually affects only HIV-positive patients with CD4 cell counts (cells of the immune system that fight infection) less than 50 cells/mm3. It is recommended that people who are likely to get DMAC be placed on preventive medications which help reduce the risk of infection. New anti-HIV combination drug therapies can increase CD4 cell counts and can reduce the level of HIV in the blood. When CD4 counts are increased, risk of DMAC infection is less. This study examines whether it is possible to stop preventive therapy for DMAC when CD4 counts are high without placing individuals at risk for getting DMAC again.
Conditions Studied
Study Locations (20)
California
- Univ of Southern California / LA County USC Med Ctr — Los Angeles
- Willow Clinic — Menlo Park
- Univ of California / San Diego Treatment Ctr — San Diego
- San Francisco AIDS Clinic / San Francisco Gen Hosp — San Francisco
- San Francisco Gen Hosp — San Francisco
- Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium — San Jose
- San Mateo AIDS Program / Stanford Univ — Stanford
- Stanford Univ Med Ctr — Stanford
New York
- SUNY / Erie County Med Ctr at Buffalo — Buffalo
- Beth Israel Med Ctr — New York
- Bellevue Hosp / New York Univ Med Ctr — New York
- Mount Sinai Med Ctr — New York
Indiana
- Indiana Univ Hosp — Indianapolis
- Division of Inf Diseases/ Indiana Univ Hosp — Indianapolis
Colorado
- Univ of Colorado Health Sciences Ctr — Denver
Florida
- Univ of Miami School of Medicine — Miami
Georgia
- Emory Univ — Atlanta
Hawaii
- Univ of Hawaii — Honolulu
Illinois
- Rush Presbyterian - Saint Luke's Med Ctr — Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000907
The ClinicalTrials.gov registry entry for NCT00000907 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 1,295 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00000907 reports 20 study locations spanning 9 distinct geographic areas — top geographies include California, New York, Indiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00000907 about?
NCT00000907 is a clinical study titled "A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DMAC) in HIV-Positive Patients". The purpose of this study is to evaluate the effects of stopping preventive therapy for DMAC in HIV-positive patients who (1) have been treated for DMAC for at least 12 months and are now free of any signs of DMAC for at least 16 weeks, and (2) have improved immune systems (CD4 cell counts greater t...
What is the current status of trial NCT00000907?
This trial is currently completed. The enrollment target is 50 participants.
What conditions does trial NCT00000907 study?
This clinical trial studies the following conditions: HIV Infections, Mycobacterium Avium-Intracellulare Infection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT00000907?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 1,295 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00000907 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.